BCR and chronic myelogenous leukemia, BCR-ABL1 positive: In our study, we demonstrated that intracellular delivery of anti-BCR/ABL antibodies by PLGA NPs exhibited an excellent anti-oncogenesis ability for CML in vitro and in vivo.